Strongbridge Biopharma plc Announces Publication of Long-term Efficacy and Safety Results for KEVEYIS® (dichlorphenamide) for the Treatment of Primary Periodic Paralysis in Muscle & Nerve
July 13, 2021 07:30 ET
|
Strongbridge Biopharma plc
~ Study Confirms Long-Term Treatment with KEVEYIS is Safe and Effective for Chronic Use ~ ~ Analyses Provide Potentially Useful Information to Help Guide Clinician Patient Counseling & Management...
Strongbridge Biopharma plc Announces Issuance of Patent for RECORLEV® (levoketoconazole) for the Treatment of Cushing’s Syndrome
June 03, 2021 16:01 ET
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., June 03, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc Announces U.S. Food & Drug Administration (FDA) Filing Acceptance of New Drug Application (NDA) for RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome
May 13, 2021 07:30 ET
|
Strongbridge Biopharma plc
~ FDA Sets Prescription Drug User Fee Act (PDUFA) Target Action Date of January 1, 2022 ~ ~ If Approved, RECORLEV® (levoketoconazole) Launch Planned for First Quarter of 2022 ~ DUBLIN, Ireland...
Strongbridge Biopharma plc Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 12, 2021 07:30 ET
|
Strongbridge Biopharma plc
~ Reports KEVEYIS® (dichlorphenamide) First Quarter 2021 Revenue of $8.4 Million, a 25 Percent Increase Compared to $6.7 Million of Revenue During First Quarter of 2020 ~ ~ Reiterates Full-Year 2021...
Strongbridge Biopharma plc to Host First Quarter 2021 Financial Results Conference Call on May 12, 2021
May 06, 2021 07:30 ET
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., May 06, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc Announces Publication of Diabetes Subgroup Analysis from Phase 3 SONICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome in Frontiers in Endocrinology
April 07, 2021 16:01 ET
|
Strongbridge Biopharma plc
RECORLEV® (levoketoconazole) Treatment Demonstrates Clinically Meaningful Improvements in Cortisol Control and Clinical Benefit in Patients with Cushing’s Syndrome and Comorbid Diabetes Mellitus ...
Strongbridge Biopharma plc Presents Detailed Results from Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2021 Annual Meeting of the Endocrine Society (ENDO)
March 20, 2021 11:00 ET
|
Strongbridge Biopharma plc
~ As Previously Reported, LOGICS Met its Primary Endpoint with Statistical Significance ~ ~ Strongbridge Recently Submitted a New Drug Application (NDA) for RECORLEV® (levoketoconazole) to the U.S....
Strongbridge Biopharma plc to Present at Oppenheimer’s 31st Annual Healthcare Conference
March 15, 2021 07:30 ET
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., March 15, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update
March 03, 2021 07:30 ET
|
Strongbridge Biopharma plc
~ Submitted New Drug Application (NDA) for RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome to U.S. Food & Drug Administration ~ ~ KEVEYIS® (dichlorphenamide)...
Strongbridge Biopharma plc Announces Submission of New Drug Application for RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome to the U.S. Food & Drug Administration
March 02, 2021 07:30 ET
|
Strongbridge Biopharma plc
~ RECORLEV® (levoketoconazole) New Drug Application is Supported by Previously-Reported Positive and Statistically Significant Results from the Phase 3 SONICS and LOGICS Studies ~ ~ Nearly 40 Percent...